Possible induction of fatty acid cyclooxygenase in mouse osteoblastic cells (MC3T3-E1) by cAMP

Activation of the peripheral sympathetic nervous system increased the expression of cyclooxygenase-2 (COX-2) mRNA in mouse calvaria

Pharmacological stimulation of adrenoceptor was demonstrated to increase the synthesis of prostaglandin (PG)-E(2), well known to modulate bone metabolism by regulating development and function of osteoclasts and osteoblasts, in cultured osteoblastic cells. Recently, intracerebroventricular (i.c.v.) injection of lipopolysaccharide (LPS), which caused the inflammatory stimuli in the brain, was demonstrated to increase the outflow of the peripheral sympathetic nervous system. In this study, to clarify the physiological role of sympathetic nerves to bone metabolism in vivo, we examined the effect of LPS (i.c.v.) on the expression of cyclooxygenase-2 (COX-2) mRNA in mouse calvaria, using reverse transcription-polymerase chain reaction analysis. The expression of COX-2 mRNA was increased by LPS (i.c.v.) in mouse calvaria. The treatment with the neurotoxin 6-hydroxydopamine or beta-blocker inhibited the central LPS-induced COX-2 mRNA in mouse calvaria. In addition, the treatment of calvaria with isoprenaline, beta-agonist, or noradrenaline increased PGE(2) synthesis in the organ culture system. These findings show that central LPS-induced COX-2 mRNA was mediated by the activation of postganglionic sympathetic nerve fibers and beta-adrenoceptor in mouse calvaria and suggest that in vivo activation of the sympathetic nervous system modulates bone metabolism.

Influence of clenbuterol on bone metabolism in exercised or sedentary rats

This paper reports that the selective beta(2)-adrenergic receptor agonist clenbuterol affects bone metabolism in growing 3-mo-old male Wistar rats treated over 8 wk. Thirty-two 3-mo-old growing Wistar rats weighing 234 +/- 2 g were assigned to a progressive isometric force, strength-training exercise program plus oral clenbuterol (2 mg x kg body wt(-1) x day(-1)) for 5 days each week, exercise program without clenbuterol 5 days each week, no exercise program plus oral clenbuterol (2 mg x kg(-1) x day(-1)) for 5 days each week, or no exercise without clenbuterol 5 days each week. At the end of 8 wk, lean mass, fat mass, and right total femoral, distal metaphyseal femoral, and diaphyseal femoral bone mineral density were measured by Hologic QDR 4,500 dual X-ray absorptiometry (DEXA) technique. Left femoral bones were harvested after death on day 58, and femoral resistance was determined by three-point bending testing. We found that fat mass was decreased in rats given strength training exercise and decreased further in rats treated with clenbuterol. Lean mass was increased in clenbuterol-treated animals. Strength-training exercise appeared to have no effect on bone mineral density, serum osteocalcin, or urinary deoxypyridinoline. However, clenbuterol treatment decreased femoral length, diameter, bone mineral density, and mechanical resistance. Clenbuterol had no effect on osteocalcin but increased urinary deoxypyridinoline. We concluded that clenbuterol treatment decreased bone mineral density and increased bone resorption independent of the level of exercise rats were given.

Effects of vigorous exercise training and beta-agonist administration on bone response to hindlimb suspension

The effectiveness of dobutamine (Dob) in preventing bone loss during 14 days of hindlimb suspension (Sus) was tested in exercise-trained (Ex; n = 25) and sedentary (Sed; n = 22) rats (age 155 days). One-half of each group was given Dob (2 mg . kg-1 . day-1) or saline (Sal). Histomorphometric measurements at midfemur revealed a 17% smaller cortical bone area (CBA) and a 32% lower periosteal mineral apposition rate (MAR) in suspended vs. nonsuspended Sed/Sal rats. Dob abolished this decline in CBA in Sed/Sus rats, probably via an attenuation of the decrease in periosteal MAR; similar but nonsignificant effects on cross-sectional moment of inertia were observed. Nonsuspended Ex rats had no change in bone CBA when CBA is indexed to body weight. Sus appeared to uncouple the relationship between soleus weight and CBA. Dob attenuated the 43% decline in soleus weight after Sus in Ex but not in Sed rats. In summary, vigorous Ex before Sus does not affect loss of bone mass due to unloading; Dob effectively maintains CBA in Sed rats subjected to suspension.

Studies on the induction of cyclooxygenase isozymes by various prostaglandins in mouse osteoblastic cell line with reference to signal transduction pathways

A mouse osteoblastic cell line MC3T3-E1 has a cyclooxygenase enzyme, and produces prostaglandin E2. When the cells were cultured in the presence of iloprost (a stable analogue of prostacyclin) or prostaglandin E1 or F2 alpha, the activity of cyclooxygenase increased in a dose- and time-dependent manner. The increase of the enzyme activity was attributed mostly to the cyclooxygenase isoform-2 because immunoprecipitation using an anti-cyclooxygenase-2 antibody removed the majority of the cyclooxygenase activity from the solubilized enzyme fraction, and the corresponding activity was detected in the immunoprecipitant. In addition, there was a marked increase in the cyclooxygenase-2 protein which was demonstrated by Western blotting. As analyzed by Northern blotting, the cyclooxygenase-2 mRNA increased and reached a maximum 1 and 3 h after the addition of iloprost and prostaglandin F2 alpha (about 15- and 60-fold increase), respectively, whereas the cyclooxygenase-1 mRNA increased slowly and only by about 3-fold. Iloprost and prostaglandin E1 stimulated the production of cAMP by 60-fold over the basal level, whereas the cAMP level was almost unchanged by prostaglandin F2 alpha. In contrast, prostaglandin F2 alpha stimulated IP3 production more efficiently than iloprost and prostaglandin E1. These results suggest that the stimulated syntheses prominently of cyclooxygenase-2 and to a lesser extent of cyclooxygenase-1 are mediated by at least two distinct signal transduction pathways involving the cAMP-synthesis stimulated by iloprost and prostaglandin E1 and the phosphoinositide turnover stimulated by prostaglandin F2 alpha.

Clenbuterol, a beta 2-receptor agonist, reduces net bone loss in denervated hindlimbs

Clenbuterol treatment for several weeks prevented up to one-third of the reduction in mineralization of femurs and tibias caused by sectioning of the sciatic nerve in young rats. The normalizing effect of clenbuterol on bone mineral content was directly proportional to similar alterations in muscle mass, which in turn could be abolished by ablation of the triceps surae or hindlimb unweighting and reduced by hypophysectomy. In contrast to the effects of inactivity, ovariectomy caused small reductions (2-4%) in bone density that were not affected by clenbuterol and were not accompanied by changes in ash weight. Together, our results suggest that the ability of beta 2-agonists to retard the loss in net muscle mass and enhance contractile tension can oppose net bone loss caused by denervation. Increases in contractile tension caused by beta 2-agonists may enhance the utility of exercise or electrical stimulation as countermeasures for the effects of scoliosis, prolonged bed rest, spinal cord injury, or weightlessness in space on bone mass.

Fatty acid cyclooxygenase activity stimulated by transforming growth factor-beta in mouse osteoblastic cells (MC3T3-E1)

Prostaglandin (PG)E2, a bone-resorption factor, was released essentially as the sole arachidonate metabolite by an osteogenic cell line cloned from mouse calvaria (MC3T3-E1). Transforming growth factor (TGF)-beta (1 ng/ml) or epidermal growth factor (EGF) (10 ng/ml) markedly stimulated the endogenous PGE2 synthesis in the presence of 5% newborn bovine serum. The serum could not be omitted even if both TGF-beta and EGF were added simultaneously. The PGE2 synthesis started after a 1-h lag phase, and reached a maximum at about 3 h after the addition of TGF-beta. The presence of TGF-beta enhanced the cyclooxygenase activity (arachidonic acid----PGH2) assayed with the microsomes or the immunoprecipitate from the solubilized enzyme. The TGF-beta-stimulated PGE2 synthesis was blocked by translation and transcription inhibitors. Furthermore, Western blot analysis using anti-cyclooxygenase antibody demonstrated a higher level of cyclooxygenase in the TGF-beta-treated cells than in the nontreated cells. These experimental results suggested an induction of cyclooxygenase by TGF-beta as previously reported for EGF (K. Yokota et al. (1986) J. Biol. Chem. 261, 15,410-15,415).